Learn about interactions between Enbrel and other medications, supplements, foods, alcohol, and more. You can also find out ...

Though we’ve recently observed some improvement in U.S. biosimilar penetration, market entry and uptake still consistently ...

Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its ...

Amgen’s venerable TNF inhibitor Enbrel (etanercept) for arthritis and other inflammatory conditions topped the list of offenders in terms of the added cost to the healthcare system, which ICER ...

The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...

Here are five top dividend stocks, including two Dividend Kings, that nervous investors should consider now for passive ...

The election results could spark market turbulence Raising cash makes sense after a 2-year market rally Sit back and let ...

Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Under the Inflation Reduction Act’s drug pricing provisions, for the ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

For patients with axial spondyloarthritis (axSpA) who do not benefit from or cannot take nonsteroidal anti-inflammatory drugs ...

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...